MedTrace Logo

Use of Pan-vascular Endothelial Growth Factor Receptor (Pan-VEGF) Blockade for the Treatment of Retinopathy of Prematurity (ROP) (Compassionate Use BLOCK-ROP)

NCT00870636 · Status: NO_LONGER_AVAILABLE · Type: EXPANDED_ACCESS

Last updated 2023-11-24

No results posted yet for this study

Summary

The purpose of this study is to provide access to intravitreal injection of Avastin in high-risk infants who do not otherwise qualify for study NCT00702819, an investigational multi-site study examining Avastin use for retinopathy of prematurity.

Conditions

  • Retinopathy of Prematurity

Interventions

DRUG

Bevacizumab (Avastin)

Dosage of 0.75mg/0.03ml intravitreal injectable, one time only.

Sponsors & Collaborators

Principal Investigators

  • Thomas Lee, M.D. · Children's Hospital Los Angeles

Eligibility

Min Age
30 Weeks
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00870636 on ClinicalTrials.gov